StockData
Niagen Bioscience, Inc. logo

Niagen Bioscience, Inc. (NAGE) stock

NAGENasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3011% below fair value
$1.94−0.10 (-4.90%)

Close on Nov 18, 2026Market cap $153.50MP/E 16.2Yield –

Niagen Bioscience revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Niagen Bioscience's revenue for the twelve months ending Sep 30, 2026 was $122.29M, down 1.9% year over year. For fiscal 2025 it was $129.42M, up 29.9% from the year before. Over ten years it grew 21.9% a year on average. The highest annual figure on record is $129.42M in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$129.42M+29.9%
FY2024Dec 31, 2024$99.60M+19.2%
FY2023Dec 31, 2023$83.57M+16.0%
FY2022Dec 31, 2022$72.05M+6.8%
FY2021Dec 31, 2021$67.45M+13.8%
FY2020Dec 31, 2020$59.26M+28.0%
FY2019Dec 31, 2019$46.29M+46.7%
FY2018Dec 31, 2018$31.56M+48.8%
FY2017Dec 30, 2017$21.20M-2.1%
FY2016Dec 31, 2016$21.66M+21.1%
FY2015Jan 2, 2016$17.88M+16.8%
FY2014Jan 3, 2015$15.31M+50.7%
FY2013Dec 28, 2013$10.16M-12.5%
FY2012Dec 29, 2012$11.61M+43.1%
FY2011Dec 31, 2011$8.11M+7.2%
FY2010Jan 1, 2011$7.57M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$27.19M-20.0%
Q2 FY2026Jun 30, 2026$29.79M-4.3%
Q1 FY2026Mar 31, 2026$31.47M+3.3%
Q4 FY2025Dec 31, 2025$33.84M+16.2%
Q3 FY2025Sep 30, 2025$33.99M+32.9%
Q2 FY2025Jun 30, 2025$31.12M+36.8%
Q1 FY2025Mar 31, 2025$30.48M+37.6%
Q4 FY2024Dec 31, 2024$29.13M+37.4%
Q3 FY2024Sep 30, 2024$25.58M+31.2%
Q2 FY2024Jun 30, 2024$22.74M+11.9%
Q1 FY2024Mar 31, 2024$22.15M-1.8%
Q4 FY2023Dec 31, 2023$21.20M+1.0%
Q3 FY2023Sep 30, 2023$19.50M+14.3%
Q2 FY2023Jun 30, 2023$20.32M+21.5%
Q1 FY2023Mar 31, 2023$22.56M+30.7%
Q4 FY2022Dec 31, 2022$21.00M+18.2%
Q3 FY2022Sep 30, 2022$17.06M-1.4%
Q2 FY2022Jun 30, 2022$16.73M-5.5%
Q1 FY2022Mar 31, 2022$17.26M+17.5%
Q4 FY2021Dec 31, 2021$17.76M+15.0%
Q3 FY2021Sep 30, 2021$17.31M+22.1%
Q2 FY2021Jun 30, 2021$17.70M+15.8%
Q1 FY2021Mar 31, 2021$14.68M+2.4%
Q4 FY2020Dec 31, 2020$15.45M+18.0%
Q3 FY2020Sep 30, 2020$14.18M+17.6%
Q2 FY2020Jun 30, 2020$15.29M+37.7%
Q1 FY2020Mar 31, 2020$14.35M+42.8%
Q4 FY2019Dec 31, 2019$13.09M+44.4%
Q3 FY2019Sep 30, 2019$12.05M+48.4%
Q2 FY2019Jun 30, 2019$11.10M+42.3%
Q1 FY2019Mar 31, 2019$10.05M+53.0%
Q4 FY2018Dec 31, 2018$9.07M+20.4%
Q3 FY2018Sep 30, 2018$8.12M+33.5%
Q2 FY2018Jun 30, 2018$7.80M+75.2%
Q1 FY2018Mar 31, 2018$6.57M+66.8%
Q4 FY2017Dec 30, 2017$7.53M–
Q3 FY2017Sep 30, 2017$6.08M–
Q4 FY2016Dec 31, 2016$4.45M–
Q3 FY2016Oct 1, 2016$3.94M–

More Niagen Bioscience figures

See a number that looks wrong?